A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence.

color blindness color universal design color vision deficiency medication adherence schizophrenia

Journal

Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700

Informations de publication

Date de publication:
09 2022
Historique:
revised: 01 06 2022
received: 28 03 2022
accepted: 02 06 2022
pubmed: 26 6 2022
medline: 30 9 2022
entrez: 25 6 2022
Statut: ppublish

Résumé

Color-blindness, or more accurately, color vision deficiency (CVD), which is the inability or decreased ability to distinguish different colors, is one of the commonest visual disorders. Patients with schizophrenia usually have multiple types of visual processing impairments, including color vision impairments. Here, we present a case of schizophrenia with congenital CVD. The patient was aware of his color deficiency since elementary school. We assessed his ability to distinguish medicines based on their color, including those that he had been previously prescribed. Although he could distinguish all of the tablets, he could not distinguish the color of the blister packs, specifically that of the bromazepam 2 mg pack (green) from the 1 mg pack (red). This case suggests that CVD patients might misunderstand the color of medications, which might lead to medication errors, or poor drug adherence. The color universal design principle should be considered when designing tablets and their blister packs, in order to improve medication adherence.

Identifiants

pubmed: 35751444
doi: 10.1002/npr2.12278
pmc: PMC9515716
doi:

Substances chimiques

Bromazepam X015L14V0O

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

384-386

Informations de copyright

© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

Références

Schizophr Res. 2019 Feb;204:162-170
pubmed: 30201549
Psychol Med. 1985 Nov;15(4):859-66
pubmed: 4080889
Neuropsychopharmacol Rep. 2022 Sep;42(3):384-386
pubmed: 35751444
Schizophr Res Cogn. 2015 Jun;2(2):46-55
pubmed: 26345525
Ophthalmol Clin North Am. 2003 Jun;16(2):179-203
pubmed: 12809157
Eye (Lond). 2010 May;24(5):747-55
pubmed: 19927164
Int J Psychiatry Clin Pract. 2020 Jun;24(2):193-200
pubmed: 31916882
Nepal Med Coll J. 2010 Jun;12(2):81-3
pubmed: 21222402
J Opt Soc Am A Opt Image Sci Vis. 2012 Mar 1;29(3):313-20
pubmed: 22472762

Auteurs

Kensuke Miyazaki (K)

Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Hirosaki-shi, Aomori, Japan.

Michiko Uchiyama (M)

Department of Hospital Pharmacy, Hirosaki-Aiseikai Hospital, Hirosaki-shi, Aomori, Japan.

Chieko Tsushima (C)

Department of Nursing, Hirosaki-Aiseikai Hospital, Hirosaki-shi, Aomori, Japan.

Kentarou Fujimoto (K)

Department of Hospital Pharmacy, Hirosaki-Aiseikai Hospital, Hirosaki-shi, Aomori, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH